Medical weight loss is obesity treatment overseen by a licensed clinician, often using FDA-approved anti-obesity medicines along with diet and activity changes.
TennCare changes the math
Most state Medicaid programs do not pay for GLP-1 drugs prescribed for obesity. KFF counted only 13 that did in January 2026 [7], and Stateline's April 2026 report names Tennessee among them [8]. TennCare's provider notice lists Wegovy and Zepbound as preferred agents effective August 1, 2025. Prior authorization is required, and the member needs a BMI of 30 or higher, or 27 or higher with a weight-related condition [1].
If you have TennCare, start with your primary care provider and ask them to submit the prior authorization. Coverage rules can change: Stateline reported that several states were weighing cuts in 2026 [8].
Sponsored placement: open.
One local practice can be featured here. This is a paid, labeled placement and never an endorsement.
Feature your practice in Nashville, from $300 a month.
That spot is sold to a local practice and marked as sponsored. We do not review or endorse sponsors.
Davidson County figures
CDC PLACES puts adult obesity at 32.0% in Nashville and 32.3% across Davidson County for 2023, with diagnosed diabetes at 10.9% and 11.2% [4] [5]. Nashville's consolidated metro government had 721,074 residents in mid-2025 [6].
If you pay cash
| Cash route | Monthly price | Notes |
|---|---|---|
| Zepbound vial or KwikPen, LillyDirect | $299 to $449 [3] | Dose sets the price; a late refill costs more |
| Wegovy injection, NovoCare | $349 [2] | Same price for every pen strength from 0.25 to 2.4 mg |
| Wegovy tablets, NovoCare | $149 to $299 [2] | 1.5 mg is $149, 4 mg is $199, 9 or 25 mg is $299 |
| Foundayo tablets, LillyDirect | $149 to $299 [9] | Varies with the dose |
| Wegovy list price on TrumpRx | $1,349 [10] | The undiscounted figure, shown for comparison |
Lilly and Novo Nordisk set these cash prices nationally, so the same order costs the same in Nashville as in Memphis. The local difference is the program fee a clinic adds. Drug-specific guides: tirzepatide in Nashville and semaglutide in Nashville.
When TennCare does not apply
- Medicare Part D. The GLP-1 Bridge runs until December 31, 2027 and sets a $50 monthly copay on Wegovy, Foundayo or the Zepbound KwikPen for enrollees who qualify [11] [12].
- Job-based plans. Lilly, citing an employer-benefits survey, says roughly half of people with employer insurance have no obesity drug coverage [13]. Where a plan does cover Zepbound, Lilly's card can bring the copay down to $25 [14].
- Sleep apnea. Zepbound also carries an approval for moderate to severe obstructive sleep apnea in adults with obesity, and some insurers handle that use separately [15].
Picking a Nashville prescriber
Look the clinician up with the Tennessee Board of Medical Examiners first [16]. Then ask whether the prescription will be a brand product or a compounded copy. Compounded semaglutide and tirzepatide have no FDA approval, and FDA does not check them for safety, effectiveness or quality [17]. For telehealth, our online program comparison and the FDA warning letter list help sort sellers.
Other Southern guides: Atlanta, New Orleans, Raleigh, Indianapolis and Charlotte. Or return to the weight loss hub.
Safety
Label warnings for Wegovy and Zepbound
People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take either drug. Stomach pain that is severe and keeps going may be pancreatitis: stop the drug and get seen. The labels also list gallbladder problems, kidney injury from dehydration, and more low blood sugar when insulin or a sulfonylurea is in the mix. Both say to stop once a pregnancy is recognized [18] [19]. Facial swelling or trouble breathing is a 911 call.
Questions people ask
Will TennCare pay for Zepbound or Wegovy in Nashville?
It can. TennCare's provider notice made Wegovy and Zepbound preferred obesity drugs on August 1, 2025. Prior authorization is required, and members qualify with a BMI of 30 or more, or 27 or more plus a weight-related condition [1].
What does a Nashville patient pay for a GLP-1 with no coverage?
How does Nashville's obesity rate compare with Davidson County's?
Is Tennessee unusual in covering these drugs through Medicaid?
Where do I confirm a Nashville prescriber's Tennessee license?
Search the Tennessee Board of Medical Examiners before the first appointment [16].
What did semaglutide do in its main obesity trial?
Adults on semaglutide 2.4 mg in the STEP 1 trial lost 14.9% of body weight on average by week 68, against 2.4% for placebo [20].
Sources
20 cited
- TennCare provider notice: obesity management agents. OptumRx for TennCare, Aug 1, 2025.
- Wegovy self-pay offer. Novo Nordisk (NovoCare Pharmacy), accessed 2026-10-17.
- Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
- PLACES place data: Nashville-Davidson, TN. CDC PLACES (2025 release, BRFSS 2023), 2023 data, 2025 release.
- PLACES county data: Davidson County, TN. CDC PLACES (2025 release, BRFSS 2023), 2023 data, 2025 release.
- QuickFacts: Nashville-Davidson metropolitan government, Tennessee. U.S. Census Bureau, QuickFacts, V2025; ACS 2020-2024.
- Medicaid Coverage of and Spending on GLP-1s. KFF, Jan 16, 2026.
- More states consider dropping GLP-1 weight loss drugs from Medicaid. Stateline (States Newsroom), Apr 30, 2026.
- Foundayo self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
- TrumpRx.gov. TrumpRx.gov (US government), accessed 2026-10-17.
- Weight loss drugs coverage. Medicare.gov (CMS), accessed 2026-10-17.
- Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
- Foundayo now available. Eli Lilly and Company, Apr 9, 2026.
- Zepbound coverage and savings. Eli Lilly and Company, accessed 2026-10-17.
- Zepbound label. DailyMed, NLM, Aug 2026.
- Tennessee Board of Medical Examiners. Tennessee Department of Health, accessed 2026-10-17.
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. US Food and Drug Administration, Oct 1, 2026.
- Wegovy label. DailyMed, NLM, Jun 2026.
- Zepbound prescribing information. US FDA (accessdata.fda.gov), Apr 2026.
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine (PubMed), Feb 10, 2021.
This page is general information, not medical advice. Talk with a licensed clinician about your own care.